Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article (0)
Advertisement

ResearchIn-Press PreviewPulmonology Open Access | 10.1172/jci.insight.172977

PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice

Luis R. Rodriguez,1 Soon Yew Tang,2 Willy Roque Barboza,1 Aditi Murthy,1 Yaniv Tomer,1 Tian-Quan Cai,3 Swati Iyer,1 Katrina Chavez,1 Ujjalkumar Subhash Das,2 Soumita Ghosh,2 Charlotte Cooper,1 Thalia T. Dimopoulos,1 Apoorva Babu,4 Caitlin F. Connelly,3 Garret A. FitzGerald,2 and Michael F. Beers1

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Rodriguez, L. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Tang, S. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Roque Barboza, W. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Murthy, A. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Tomer, Y. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Cai, T. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Iyer, S. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Chavez, K. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Das, U. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Ghosh, S. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Cooper, C. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Dimopoulos, T. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Babu, A. in: PubMed | Google Scholar |

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Connelly, C. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by FitzGerald, G. in: PubMed | Google Scholar

1Pulmonary, Allergy, and Critical Care Division Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

3Calico Life Sciences, Philadelphia, United States of America

4PENN-CHOP Lung Biology Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America

5Calico Life Sciences, South San Francisco, United States of America

Find articles by Beers, M. in: PubMed | Google Scholar |

Published November 7, 2023 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.172977.
Copyright © 2023, Rodriguez et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 7, 2023 - Version history
View PDF
Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a chronic parenchymal lung disease characterized by repetitive alveolar cell injury, myofibroblast proliferation, and excessive extracellular matrix deposition for which unmet need persists for effective therapeutics. The bioactive eicosanoid, prostaglandin F2a, and its cognate receptor FPr (Ptfgr) are implicated as a TGFβ1 independent signaling hub for IPF. To assess this, we leveraged our published murine PF model (IER-SftpcI73T) expressing a disease-associated missense mutation in the surfactant protein C (Sftpc) gene. Tamoxifen treated IER-SftpcI73T mice develop an early multiphasic alveolitis and transition to spontaneous fibrotic remodeling by 28 days. IER-SftpcI73T mice crossed to a Ptgfr null (FPr-/-) line showed attenuated weight loss and gene dosage dependent rescue of mortality compared to FPr+/+ cohorts. IER-SftpcI73T/FPr-/- mice also showed reductions in multiple fibrotic endpoints for which administration of nintedanib was not additive. Single cell RNA sequencing, pseudotime analysis, and in vitro assays demonstrated Ptgfr expression predominantly within adventitial fibroblasts which were reprogrammed to an “inflammatory/transitional” cell state in a PGF2a/ FPr dependent manner. Collectively, the findings provide evidence for a role for PGF2a signaling in IPF, mechanistically identify a susceptible fibroblast subpopulation, and establish a benchmark effect size for disruption of this pathway in mitigating fibrotic lung remodeling.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (November 7, 2023): In-Press Preview
  • Version 2 (December 22, 2023): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (0)

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts